Mounjaro Proven More Effective Than Ozempic for Weight Management

United States – A new study conducted in JAMA Internal Medicine addresses the efficacy of tirzepatide (Mounjaro) concerning semaglutide (Ozempic) as weight reduction agents in people with overweight or obesity.

Key Findings

According to findings led by Dr. Nicholas Stucky of Truveta Inc., tirzepatide users demonstrated significantly greater weight loss outcomes compared to those using semaglutide. The study highlighted that individuals treated with tirzepatide were more likely to achieve clinically meaningful weight loss and experience larger reductions in body weight, as reported by The Hills.

Study Details

The study enlisted more than 18,000 clinically diagnosed obesity with type 2 diabetes patients who received tirzepatide or semaglutide between May 2022 and September 2023. Approved at first for diabetic patients, both drugs have been proven effective when used in weight loss management.

One must note that participants using Mounjaro lost an average weight of 6% on average after 3 months while those on Ozempic lost less than 4%. A study of one-year showed that, Mounjaro users had lost approximately 15% of their weight while those who used Ozempic had lost about 8% only.

Mechanism of Action

Both medications work through the prolongation of release of GLP-1, an intestinal peptide used for the maintenance of glycemic control and satiety. Mounjaro also stimulates the secretion of GIP, another gut hormone, which could further aid the drug’s weight loss abilities, as reported by The Hills.

What’s your Reaction?
+1
0
+1
1
+1
0
+1
0
+1
0
+1
0